ArticleEuropean cardiology2025
Decoding Immune Influence: A Mendelian Randomisation Study on Dilated Cardiomyopathy.
Article in European cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dilated cardiomyopathy (DCM) is a significant contributor to heart failure, originating from complex interactions between genetic and environmental factors. Although the immune system has been implicated in various cardiovascular diseases, its precise role in DCM pathogenesis remains ambiguous. This study uses Mendelian randomisation (MR) to explore the causal relationship between diverse immune cell traits and DCM risk. Methods: We conducted a two-sample MR analysis using summary-level data from genome-wide association studies of 731 immune cell traits and DCM. Our primary method employed fixed- and random-effects inverse-variance weighting, complemented by sensitivity analyses - such as MR-Egger, Mendelian Randomisation-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) - to address potential pleiotropy. Additionally, genetic mapping and pathway enrichment analyses were performed on the key immune trait associated with DCM risk. Results: Our analysis revealed that an increased relative count of CD4 Conclusion: These findings provide novel evidence supporting a causal role of elevated CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.